Ovation Science (XCNQ:OVAT) Debt-to-EBITDA : -0.27 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ovation Science Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ovation Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.17 Mil. Ovation Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.02 Mil. Ovation Science's annualized EBITDA for the quarter that ended in Dec. 2023 was C$-0.72 Mil. Ovation Science's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.27.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ovation Science's Debt-to-EBITDA or its related term are showing as below:

XCNQ:OVAT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.6 Med: -0.27 Max: -0.05
Current: -0.25

During the past 7 years, the highest Debt-to-EBITDA Ratio of Ovation Science was -0.05. The lowest was -0.60. And the median was -0.27.

XCNQ:OVAT's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs XCNQ:OVAT: -0.25

Ovation Science Debt-to-EBITDA Historical Data

The historical data trend for Ovation Science's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovation Science Debt-to-EBITDA Chart

Ovation Science Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.29

-0.05

-0.25

Ovation Science Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.06	-0.12	-0.13	-0.25	-0.27

Competitive Comparison of Ovation Science's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovation Science's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ovation Science's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ovation Science's Debt-to-EBITDA falls into.

Ovation Science Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ovation Science's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.174	+	0.018)	/	-0.779
	=	-0.25

Ovation Science's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.174	+	0.018)	/	-0.716
	=	-0.27

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Ovation Science (XCNQ:OVAT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Ovation Science Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ovation Science's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovation Science (XCNQ:OVAT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ovation Science Inc (XCNQ:OVAT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

OVATF:USA

Address

625 Howe Street, Suite 1140, Vancouver, BC, CAN, V6C 2T6

Website

https://www.ovationscience.com

Ovation Science Inc is a Canada-based company mainly engaged in the business of sub-licensing rights to use Invisicare, a patented drug delivery technology used in topical and transdermal skin products containing hemp seed oil and cannabis products. The company also holds the right to manufacture, distribute, sell, market, sub-license and promote products formulated with Invisicare and containing cannabis products including cannabinoids, hemp seed oil and any synthetic derivatives of cannabis. It also develops formulas for skin product lines including topical and transdermal creams and lotions containing hemp seed oil and cannabis.

Executives

David K. Ryan

Director

Ovation Science (XCNQ:OVAT) Headlines

No Headlines